Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

4 Biotech Stocks Analysts Like This Tuesday

|Includes: BioDelivery Sciences International, Inc. (BDSI), CTLT, FCSC, SCYX

Ah yes, the joys of free enterprise, which is never free of anything be it taxes, bills, or stress.” ― E.A. Bucchianeri, Vocation of a Gadfly

The biotech sector started the new trading week on the wrong foot yesterday.  The major biotech ETFs posted losses of between a half and one percent Monday.  However, this was significantly off the sector's lows earlier in the day.

Futures are up nicely on some better than expected earnings reports pre-market.  While we await the market to open this Tuesday, here are four biotech stocks getting positive analyst commentary from analysts today.

Cantor Fitzgerald reissues its Overweight rating and $8 price target on BioDelivery Sciences (BDSI) after that company made an acquisition recently.  Here is their post purchase take on the small biopharma concern.

Post BDSI’s recent acquisition of U.S. commercial rights to Symproic, and equity raise, we are updating our model and reiterating our Overweight rating and 12-month price target of $8. BDSI has built a strong commercial team around Belbuca, and the acquisition leverages the company’s commercial strengths, and footprint, to grow its portfolio. We view the acquisition of Symproic as a positive as it diversifies the company’s revenue away from a single product, Belbuca, and can add a meaningful revenue contribution of $75MM + without the need for any significant increase in spending.

UBS upgrades Catalent (CTLT) from Neutral to Buy this morning.  It also raises its price target to $54 from $43 previously.  Here is the synopsis of that analyst call.

The company's acquisition of Paragon "significantly increases the exposure to the rapidly growing biologic production market" which is "arguably the most attractive sub segment within the broader life science tools sector today." The analyst models the deal to be accretive by over 200bps to Catalent's revenue and EBITDA in the long term and potentially higher in the near term, adding that his price target assumes EBITDA multiple of 14-times - a 2-turn premium to the stock's long-term average. The analyst further notes that his "recent diligence" suggests that the "bullishness about the gene therapy market is warranted."

Image result for act now

10 Simple Rules To Trade Options Like A Pro' from our friends at Investors Alley is a good quick overview on using option strategies to mitigate risk and enhance returns in your portfolio. These strategies are well suited to high beta sectors like biotech where option premiums tend to be large. The report is now available free via download HERE

Next up is Fibrocell Science (FCSC) which H.C. Wainwright reiterates a Buy rating and whopping $22 price target  (the stock current trades around $2.50 a share).  Here is the commentary from that analyst call.

Valuation and risks to price target achievement. We reiterate our Buy rating and $22 price target. We point out that the large delta between the current share price and our price target is driven by the company’s relatively low share count. Further, we believe that the current share price does not reflect, despite the low patient numbers, the ability of FCX-007 to address RDEB patients’ needs, as well as the accelerated potential from a regulatory standpoint, including a Priority Review Voucher (PRV).”

The stock was up over 40% Monday in trading on this news.

Finally, Needham maintains its Buy rating and $5 price target on SCYNEXIS (SCYX) today.  A different analyst at H.C. Wainwright does the same with the following commentary

We think it’s already becoming clear that ibrex will eventually have a role to play as the only oral fungicidal therapy with activity against azole-resistant infections, to expand options for longer-duration therapy in the outpatient setting. With Candida glabrata widespread and largely multidrug-resistant, and Candia auris finally gaining widespread attention and alarm (mortality rate as high as 60%), as evidenced by prominent New York Times feature ten days ago, the acute need for an efficacious oral therapy to provide the necessary weeks to months of dosing, is obvious. That said, we think it’s still too soon to plot ibrexfungerp’s path to approval to treat such infections, or to project the commercial opportunity.”

And those are four small cap names getting analyst 'shout outs' this Tuesday.

He's spending a year dead for tax reasons.” ― Douglas Adams, The Hitchhiker's Guide to the Galaxy

Thank You & Happy Hunting,

Bret Jensen

Founder, The Biotech Forum, The Busted IPO Forum & The Insiders Forum

Image result for available now

We just published an extensive free report on a small biopharma with a key PDUFA date fast approaching. If you are signed up to receive our free reports, you should receive this research automatically in your email today. If you want this investment analysis and are not registered yet, just go to bretjenseninvests.com and hit the 'free reports' tab to download this latest report. This action will also register you for all the free reports we put out going forward as published as well.